Imunon, Inc. (IMNN) director granted 6,934 shares in lieu of fees

Rhea-AI Filing Summary

Pellizzari Christine A reported acquisition or exercise transactions in this Form 4 filing.

Imunon, Inc. director Christine A. Pellizzari received a grant of 6,934 shares of common stock on July 31, 2026, at a stated value of $1.59 per share. The shares were granted in lieu of cash for a portion of her board fees, bringing her direct holdings to 15,076 shares.

Insider Trade Summary

Net Buyer: 6,934 shares

Net Buy 1 txn

Insider Pellizzari Christine A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	6,934	$1.59	$11K

Holdings After Transaction: Common Stock — 15,076 shares (Direct)

Footnotes (1)

1. F1. Stock granted in lieu of cash for portion of board fees

Key Figures

Shares granted: 6,934 shares Grant value per share: $1.59 per share Shares owned after transaction: 15,076 shares

3 metrics

Shares granted 6,934 shares Stock granted in lieu of cash for portion of board fees on July 31, 2026

Grant value per share $1.59 per share Stated value for the July 31, 2026 stock grant

Shares owned after transaction 15,076 shares Total direct Imunon common stock holdings following the grant

Key Terms

grant, award, or other acquisition, stock granted in lieu of cash, Common Stock

3 terms

grant, award, or other acquisition financial

"Transaction coded as a grant, award, or other acquisition (code A)."

stock granted in lieu of cash financial

"Stock granted in lieu of cash for portion of board fees."

Common Stock financial

"Security title reported for the transaction is Common Stock."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/04/2026 - 04:17 PM Accepted by SEC EDGAR 08/04/2026 - 04:17 PM Learn about SEC filing dates

FAQ

What transaction did Imunon (IMNN) director Christine A. Pellizzari report on this Form 4?

Christine A. Pellizzari reported a grant of 6,934 shares of Imunon common stock on July 31, 2026. The stock was issued in lieu of cash for part of her board fees at a stated value of $1.59 per share.

Was the Imunon (IMNN) stock grant to Christine Pellizzari an open-market purchase?

No. The filing shows the 6,934 shares were granted in lieu of cash for a portion of board fees. The transaction is coded as a grant, award, or other acquisition (code A), not a market purchase.

How many Imunon (IMNN) shares does Christine Pellizzari hold after this grant?

After the reported grant, Christine A. Pellizzari directly holds 15,076 shares of Imunon common stock. This figure reflects her total direct ownership immediately following the July 31, 2026 stock compensation transaction.

At what price was the Imunon (IMNN) director stock grant valued?

The 6,934-share grant to Christine A. Pellizzari was valued at $1.59 per share. This per-share figure represents the stated value used for the stock issued in lieu of cash board fees on July 31, 2026.

Was the Imunon (IMNN) Form 4 transaction made under a Rule 10b5-1 trading plan?

The Form 4 indicates the transaction was not made pursuant to a Rule 10b5-1 plan. The filing’s plan-related checkbox is unchecked, signaling the grant was not executed under a pre-arranged trading arrangement.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pellizzari Christine A

(Last) (First) (Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE NEW JERSEY 08648

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/31/2026		A		6,934(1)	A	$1.59	15,076	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Stock granted in lieu of cash for portion of board fees

	/s/ Susan Eylward, Attorney-in-Fact for Christine Pellizzari	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)